A carregar...
Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma
OBJECTIVE: Brentuximab vedotin (BV) is an FDA approved anti-CD30 antibody drug conjugate potently active in Hodgkin lymphoma (HL). Trials of BV with doxorubicin, vinblastine, and dacarbazine (AVD-BV) excluded patients with HIV. We studied the safety of (AVD-BV) in newly diagnosed HIV-associated clas...
Na minha lista:
| Publicado no: | AIDS |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5832596/ https://ncbi.nlm.nih.gov/pubmed/29280762 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAD.0000000000001729 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|